Across the world, Tobacco Harm Reduction (THR) is increasingly viewed as a practical, science-driven strategy for improving public health. It is grounded in the understanding—highlighted by decades of tobacco control efforts—that although quitting entirely is the healthiest choice, many adult smokers will still seek nicotine. THR therefore aims to offer scientifically verified, lower-risk alternatives that reduce exposure to harmful substances, serving as a complement to existing tobacco control policies rather than a replacement.
In Nigeria, where about 3.7 percent of adults smoke (World Health Organization, Global Adult Tobacco Survey Nigeria 2023), adopting a risk-proportionate THR framework offers a valuable opportunity. By combining scientific evidence, effective regulations, and accurate public communication, the country can significantly lessen smoking-related harm while helping consumers make informed decisions.
Public Health England’s 2022 review found that vaping is at least 95 percent less harmful than smoking because it eliminates smoke and tar. Likewise, the U.S. Food and Drug Administration (FDA) has permitted certain heated tobacco and oral nicotine products to be marketed as Modified Risk Tobacco Products, recognising that they expose users to reduced toxicant levels.
To unlock the benefits of THR in Nigeria, the country must implement a clear regulatory structure based on product risk. This should involve rigorous testing and certification processes, accurate labeling, and responsible marketing. Aligning fiscal policy with harm reduction principles is equally important—excise taxes should correspond to product risk so that non-combustible products are not taxed more than cigarettes. This alignment would make it easier for adult smokers who cannot or will not quit to transition to safer alternatives.
This direction aligns with the World Health Organization Framework Convention on Tobacco Control (WHO FCTC), which identifies harm reduction as a valid component of comprehensive tobacco control in Article 1(d). It also mirrors successful regulatory approaches used in the United Kingdom, Sweden, and Japan, where harm-reduction strategies have contributed to notable drops in smoking rates without weakening tobacco control efforts.
Transparency and public trust must guide implementation. Collaboration among policymakers, health professionals, and manufacturers is needed to ensure product safety, responsible messaging, and evidence-based regulation. Civil society and healthcare providers also have significant roles to play. A 2024 study in the International Journal of Medical Students revealed that although Nigerian medical students were familiar with THR ideas, many were unsure about how to apply them, highlighting the need for balanced education within the health sector.
In addition, establishing independent advisory bodies and effective post-market monitoring systems will strengthen oversight, track how consumers use reduced-risk products, and help assess health impacts. These structures will boost confidence in Nigeria’s THR efforts while supporting a transparent, science-focused model that integrates harm reduction into the broader tobacco control landscape.
Ultimately, Tobacco Harm Reduction offers a logical, evidence-guided, and complementary pathway to better public health. With the right mixture of scientific rigor, appropriate regulation, and public education, Nigeria can meaningfully reduce the harms associated with smoking while giving adults access to safer alternatives. The chance to make real progress is clear, and embracing a balanced, evidence-driven strategy is more important than ever.
